The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.

Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

There's some rumbling going on within Pfizer's investment community, as an activist hedge fund says that the company's ...

Pfizer's Q3 consensus estimate is likely to be exceeded. Despite the underperformance over the past two months, see why PFE ...

A key panel of U.S. health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...

Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...